CA1062501A - Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin - Google Patents

Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin

Info

Publication number: CA1062501A
Authority: CA; Canada
Prior art keywords: standard; blood plasma; plasma; time; factor
Prior art date: 1976-07-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA257,483A

Other languages

English (en)

Inventor

James W. Eichelberger

Frederick M. Kent

Michael Sokol

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bio Data Corp

Original Assignee

Bio Data Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-07-21

Filing date

1976-07-21

Publication date

1979-09-18

1976-07-21 Application filed by Bio Data Corp filed Critical Bio Data Corp

1976-07-21 Priority to CA257,483A priority Critical patent/CA1062501A/fr

1979-09-18 Application granted granted Critical

1979-09-18 Publication of CA1062501A publication Critical patent/CA1062501A/fr

Status Expired legal-status Critical Current

Links

210000002381 plasma Anatomy 0.000 title claims abstract description 196
238000000034 method Methods 0.000 title claims abstract description 40
239000003114 blood coagulation factor Substances 0.000 title claims abstract description 34
102000015081 Blood Coagulation Factors Human genes 0.000 title claims abstract description 33
108010039209 Blood Coagulation Factors Proteins 0.000 title claims abstract description 33
230000007812 deficiency Effects 0.000 title abstract description 45
238000006911 enzymatic reaction Methods 0.000 title abstract 2
108010049003 Fibrinogen Proteins 0.000 claims abstract description 65
102000008946 Fibrinogen Human genes 0.000 claims abstract description 65
229940012952 fibrinogen Drugs 0.000 claims abstract description 65
230000003287 optical effect Effects 0.000 claims abstract description 65
230000000694 effects Effects 0.000 claims description 115
206010053567 Coagulopathies Diseases 0.000 claims description 53
230000035602 clotting Effects 0.000 claims description 53
238000005065 mining Methods 0.000 claims 1
230000002950 deficient Effects 0.000 abstract description 23
230000008569 process Effects 0.000 abstract description 9
238000012360 testing method Methods 0.000 description 103
230000006870 function Effects 0.000 description 39
239000003153 chemical reaction reagent Substances 0.000 description 26
238000003556 assay Methods 0.000 description 25
229960004072 thrombin Drugs 0.000 description 19
102100022641 Coagulation factor IX Human genes 0.000 description 18
108010076282 Factor IX Proteins 0.000 description 18
108090000190 Thrombin Proteins 0.000 description 18
229960004222 factor ix Drugs 0.000 description 18
108010054218 Factor VIII Proteins 0.000 description 17
102000001690 Factor VIII Human genes 0.000 description 17
229960000301 factor viii Drugs 0.000 description 17
102000009123 Fibrin Human genes 0.000 description 13
108010073385 Fibrin Proteins 0.000 description 13
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
108010000499 Thromboplastin Proteins 0.000 description 13
102000002262 Thromboplastin Human genes 0.000 description 13
229950003499 fibrin Drugs 0.000 description 13
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
238000005755 formation reaction Methods 0.000 description 11
108010094028 Prothrombin Proteins 0.000 description 10
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
102100027378 Prothrombin Human genes 0.000 description 9
239000001110 calcium chloride Substances 0.000 description 9
229910001628 calcium chloride Inorganic materials 0.000 description 9
239000012895 dilution Substances 0.000 description 9
238000010790 dilution Methods 0.000 description 9
229940039716 prothrombin Drugs 0.000 description 9
230000000994 depressogenic effect Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
239000003146 anticoagulant agent Substances 0.000 description 6
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
230000023555 blood coagulation Effects 0.000 description 5
238000007689 inspection Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
208000009292 Hemophilia A Diseases 0.000 description 4
230000008859 change Effects 0.000 description 4
239000004020 conductor Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000006116 polymerization reaction Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000003813 thumb Anatomy 0.000 description 4
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229960000182 blood factors Drugs 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102100023804 Coagulation factor VII Human genes 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
201000003542 Factor VIII deficiency Diseases 0.000 description 2
108010071289 Factor XIII Proteins 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000028221 Mild hemophilia A Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001174 ascending effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
229940012444 factor xiii Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000012886 linear function Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 1
101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
238000012274 Preoperative evaluation Methods 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
238000013096 assay test Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007819 clotting time assay Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
239000000835 fiber Substances 0.000 description 1
208000009429 hemophilia B Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
229940039790 sodium oxalate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)

CA257,483A 1976-07-21 1976-07-21 Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin Expired CA1062501A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA257,483A CA1062501A (fr)	1976-07-21	1976-07-21	Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA257,483A CA1062501A (fr)	1976-07-21	1976-07-21	Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin

Publications (1)

Publication Number	Publication Date
CA1062501A true CA1062501A (fr)	1979-09-18

Family

ID=4106476

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA257,483A Expired CA1062501A (fr)	1976-07-21	1976-07-21	Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin

Country Status (1)

Country	Link
CA (1)	CA1062501A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3225998A1 (fr) *	2016-03-31	2017-10-04	Siemens Healthcare Diagnostics Products GmbH	Procede de determination de fibrinogenes
CN108872619A (zh) *	2017-04-24	2018-11-23	希森美康株式会社	血液样本的分析方法以及分析装置
EP4394045A1 (fr)	2022-12-28	2024-07-03	Siemens Healthcare Diagnostics Products GmbH	Procédé de détermination du fibrinogène

1976
- 1976-07-21 CA CA257,483A patent/CA1062501A/fr not_active Expired

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3225998A1 (fr) *	2016-03-31	2017-10-04	Siemens Healthcare Diagnostics Products GmbH	Procede de determination de fibrinogenes
WO2017167706A1 (fr)	2016-03-31	2017-10-05	Siemens Healthcare Diagnostics Products Gmbh	Procédé de dosage de fibrinogène
CN108139411A (zh) *	2016-03-31	2018-06-08	西门子医学诊断产品有限责任公司	用于确定纤维蛋白原的方法
JP2019502094A (ja) *	2016-03-31	2019-01-24	シーメンスヘルスケアダイアグノスティクスプロダクツゲゼルシヤフトミツトベシユレンクテルハフツング	フィブリノゲンを決定する方法
US10822636B2 (en)	2016-03-31	2020-11-03	Siemens Healthcare Diagnostics Products Gmbh	Method for determining fibrinogen and automatic analyzer
CN108872619A (zh) *	2017-04-24	2018-11-23	希森美康株式会社	血液样本的分析方法以及分析装置
US10739360B2 (en)	2017-04-24	2020-08-11	National University Corporation Nagoya University	Method for analyzing blood specimen, and analyzer
EP3396384B1 (fr) *	2017-04-24	2020-11-18	Sysmex Corporation	Procédé et appareil pour déterminer un échantillon sanguin
CN108872619B (zh) *	2017-04-24	2024-06-11	希森美康株式会社	血液样本的分析方法以及分析装置
EP4394045A1 (fr)	2022-12-28	2024-07-03	Siemens Healthcare Diagnostics Products GmbH	Procédé de détermination du fibrinogène

Publication	Publication Date	Title
US4047890A (en)	1977-09-13	Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas
Ray et al.	1990	The dependence of the International Sensitivity Index on the coagulometer used to perform the prothrombin time
EP0434377B1 (fr)	1995-08-23	Procédé pour déterminer les niveaux de facteurs de coagulation extrinsèques et intrinsèques et de protéine C
US5981285A (en)	1999-11-09	Method and apparatus for determining anticoagulant therapy factors
US5156974A (en)	1992-10-20	Method for determining the fibrinogen level of a blood sample
JP7619724B2 (ja)	2025-01-22	血液凝固時間測定方法
EP0178910A2 (fr)	1986-04-23	Méthodes pour la surveillance de la coagulation du sang
JP7712020B2 (ja)	2025-07-23	血液凝固時間測定方法
Karon et al.	2008	Accuracy of capillary whole blood international normalized ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 point-of-care analyzers
van den Besselaar	2001	Accuracy, precision, and quality control for point-of-care testing of oral anticoagulation
Koepke	2000	Point-of-care coagulation testing
US20100235103A1 (en)	2010-09-16	Method and apparatus for evaluating prothrombotic conditions
JPH11142412A (ja)	1999-05-28	自動分析装置
CA1062501A (fr)	1979-09-18	Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin
US8445287B2 (en)	2013-05-21	Method and apparatus for determining anticoagulant therapy factors
CN109406461A (zh)	2019-03-01	血小板聚集率测量结果判定方法及血小板聚集仪的标定方法
US20040219680A1 (en)	2004-11-04	Method and apparatus for determining anticoagulant therapy factors
EP2546637B1 (fr)	2014-05-14	Procédé et appareil pour déterminer des facteurs de traitement anticoagulant
US7901694B2 (en)	2011-03-08	Method and apparatus for determining anticoagulant therapy factors
LaForce et al.	1992	Evaluation of the SonoClot Analyzer for the measurement of platelet function in whole blood
Pan et al.	1996	Modified microsample ACT test for heparin monitoring
EP1907866B1 (fr)	2011-07-27	Procédé et appareil de détermination de facteurs de thérapie anticoagulation
WO2023032978A1 (fr)	2023-03-09	Méthode de détection d'anomalie de réaction de coagulation sanguine
Bazaev et al.	2015	Modern methods for measuring parameters of blood coagulation
JPS58172537A (ja)	1983-10-11	光散乱測定装置